Kyowa Kirin Co., Ltd. (4151.T) JPX

Currency In JPY

Key Executives

Name	Title	Pay	Year Born
Abdul Hafeez Mullick	President, Chief Executive Officer & Representative Director	215M	1967
Nathan Hawes	Global Operational & Digital Transformation Head	0	N/A
Naohiko Kubo	Global Finance Head & Accounting Manager	0	N/A
Masahiro Hara	Global Procurement Head	0	N/A
Takeyoshi Yamashita	Executive VP, Chief Scientific Officer & Director	0	1961
Eslie Dennis	Global Medical Affairs Head	0	N/A
Stacey Minton	Global Corporate Communications Head	0	N/A
Katsuyoshi Tsukii	Executive Officer, VP & Head of Development Division	0	N/A
Shoko Itagaki	Managing Executive Officer, Chief People Officer & Global Human Resources Head	0	N/A
Yoshifumi Torii	Executive Officer, Chief Medical Officer & Global Development Head	0	N/A
Nilay Gami	Head of Global Pharmacovigilance	0	N/A
Takaaki Uochi	Head of Global Compliance & Risk Management	0	N/A
Koichi Nagano	Executive Officer and Head of Tokyo Branch - Sales & Marketing Division	0	N/A
Koji Igarashi	Chief Financial Officer	0	N/A
Kazuki Nemoto	Head of Global Legal	0	N/A
Yasuo Fujii	Chief Business Officer, VP, Managing Executive Officer & Global Business Development Head	0	1964

Name

Title

Pay

Year Born

Abdul Hafeez Mullick

President, Chief Executive Officer & Representative Director

215M

1967

Nathan Hawes

Global Operational & Digital Transformation Head

N/A

Naohiko Kubo

Global Finance Head & Accounting Manager

N/A

Masahiro Hara

Global Procurement Head

N/A

Takeyoshi Yamashita

Executive VP, Chief Scientific Officer & Director

1961

Eslie Dennis

Global Medical Affairs Head

N/A

Stacey Minton

Global Corporate Communications Head

N/A

Katsuyoshi Tsukii

Executive Officer, VP & Head of Development Division

N/A

Shoko Itagaki

Managing Executive Officer, Chief People Officer & Global Human Resources Head

N/A

Yoshifumi Torii

Executive Officer, Chief Medical Officer & Global Development Head

N/A

Nilay Gami

Head of Global Pharmacovigilance

N/A

Takaaki Uochi

Head of Global Compliance & Risk Management

N/A

Koichi Nagano

Executive Officer and Head of Tokyo Branch - Sales & Marketing Division

N/A

Koji Igarashi

Chief Financial Officer

N/A

Kazuki Nemoto

Head of Global Legal

N/A

Yasuo Fujii

Chief Business Officer, VP, Managing Executive Officer & Global Business Development Head

1964

Description

Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, central nervous system disorders, and immunology. Its extensive product portfolio includes established medications such as ABSTRAL, a sublingual fentanyl formulation for managing breakthrough pain in cancer patients; ALLELOCK, an antihistamine for various allergic conditions; and CONIEL, a calcium channel blocker prescribed for hypertension and angina. Kyowa Kirin also provides a range of advanced biological and specialized treatments. These encompass Crysvita, a recombinant human monoclonal IgG1 antibody targeting fibroblast growth factor 23, and blood-related therapies like ESPO (human erythropoietin), NESP (an erythropoiesis stimulating agent), and GRAN (a human colony-stimulating factor). Further products in its lineup address diverse medical needs: G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for opioid-induced constipation; Nouriast/Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. Other significant offerings are PecFent, a nasally administered spray; POTELIGEO, a humanized monoclonal antibody targeting CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a recombinant protein promoting platelet production; and SANCUSO for managing nausea and vomiting. Beyond its current offerings, Kyowa Kirin is actively involved in pipeline development, notably through a strategic collaboration with Amgen Inc. for the joint development and commercialization of KHK4083. This Phase 3-ready, fully human anti-OX40 monoclonal antibody is being developed to treat atopic dermatitis. Established in Tokyo, Japan, in 1949, the company changed its name from Kyowa Hakko Kirin Co., Ltd. to Kyowa Kirin Co., Ltd. in June 2019. It operates as a subsidiary of Kirin Holdings Company, Limited.